Publications by authors named "Jorge Negueb Martinez-Hernandez"
Article Synopsis
- A study was conducted in Mexico to compare early palliative care (EPC) with standard oncological care (SOC) in patients with metastatic non-small cell lung cancer (NSCLC). !* -
- Patients in the EPC group had access to a multidisciplinary team that included psychologists, nutritionists, and specialized nurses, aiming to improve their quality of life and symptom management. !* -
- Results showed that patients receiving EPC had a median overall survival of 18.1 months, significantly longer than the 10.5 months for those receiving SOC alone, highlighting the potential benefits of integrating palliative care in cancer treatment. !*
Background: Up-to-date oncological therapy has been accomplished through the results of clinical trials (CTs). We analyzed the overall survival (OS) of patients with non-small cell lung cancer (NSCLC) and its relation to CT enrollment.
Methods: The study included 1,042 patients with advanced NSCLC treated at the Instituto Nacional de Cancerología.
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Target Oncol
October 2016
Background: C-met and its ligand, hepatocyte growth factor (HGF) have been associated with the resistance mechanism of EGFR-TKIs. HGF was evaluated as a clinical-marker of response in NSCLC patients treated with afatinib.
Methods: Sixty-six patients with stage IIIB/IV lung adenocarcinoma and progression to any-line chemotherapy received afatinib 40 mg/day.
Background: Afatinib has shown long progression free survival and improvement in quality of life in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Although afatinib causes acneiform rash, it can be manageable. Tetracyclines are usually used to treat it; nonetheless, there is no trial that evaluates their prophylactic efficacy on afatinib induced-skin toxicities (AIST).
View Article and Find Full Text PDF